Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 70
  • Home
  • Print this page
  • Email this page
Year : 2017  |  Volume : 12  |  Issue : 4  |  Page : 265-273

Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies

1 Department of Virology, Pasteur Institute of Iran, Tehran, I.R., Iran
2 Department of Dermatology, Tehran University of Medical Sciences, Tehran, I.R., Iran
3 Department of Immunology, Pasteur Institute of Iran, Tehran, I.R., Iran
4 Department of Parasitology, Pasteur Institute of Iran, Tehran, I.R., Iran

Correspondence Address:
Kayhan Azadmanesh
Department of Virology, Pasteur Institute of Iran, Tehran, I.R.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1735-5362.212043

Rights and Permissions

Current licensed and commercially available prophylactic human papillomavirus (HPV) vaccines (Cervarix and quadrivalent/nine valents Gardasil) are based on major capsid protein L1 virus-like particles (VLPs) production which are expensive and type specific. Minor capsid L2-RG1 linear epitope (17-36) is a known candidate for induction of cross-neutralizing antibodies to develop low-cost pan-HPV vaccines. Herein, we report construction and expression of a three tandem repeats of L2-RG1 derived from HPV16 and 18 fused with the same head to tail pattern (HPV16:17-36×3+ HPV18:17-36×3; hereafter termed dual-type fusion L2 peptide) in E. coli and provide the results of its immunogenicity in mice. SDS-PAGE and western blot analyses indicated proper expression of the peptide that could be further purified by Ni-NTA affinity chromatography via the located C-terminal 6xHis-tag. Mice immunized by formulation of the purified peptide and Freund adjuvant raised neutralizing antibodies which showed proper cross reactivity to HPV L2 (11-200) of types: 18, 16, 31 and 45 (which totally are responsible for 90% of cervical cancers) and efficiently neutralized HPV18/16 pseudoviruses in vitro. Our results imply the possibility of development of a simple, low-cost preventive HPV vaccine based on this dual-type fusion L2 peptide in bacterial expression system with broad spectrum.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded129    
    Comments [Add]    
    Cited by others 1    

Recommend this journal